Roivant Launches New Clinical Trial for LPP
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy ROIV?
Source: Newsfilter
- New Clinical Trial Launch: Roivant initiated a seamless Phase 2b/3 clinical trial for Lichen planopilaris (LPP) in March 2026, marking the fourth indication in its late-stage development program, demonstrating the company's proactive approach to addressing critical unmet therapeutic needs.
- FDA Priority Review: The FDA has granted Priority Review for the New Drug Application (NDA) of brepocitinib, with a target action date expected in Q3 2026, potentially accelerating market access for this treatment to meet urgent patient needs in LPP.
- Clinical Data Support: Strong mechanistic rationale and clinically meaningful results from an investigator-initiated placebo-controlled study support the rapid development of brepocitinib in LPP, highlighting its potential efficacy in this challenging condition.
- Multi-Indication Strategy: CEO Ben Zimmer emphasized that expanding brepocitinib into LPP aligns with the company's strategy of developing treatments for highly morbid orphan conditions, anticipating synergistic effects with other indications like dermatomyositis to enhance market competitiveness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ROIV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ROIV
Wall Street analysts forecast ROIV stock price to fall
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 27.750
Low
22.00
Averages
27.63
High
33.00
Current: 27.750
Low
22.00
Averages
27.63
High
33.00
About ROIV
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Priovant Launches Phase 2b/3 Trial for Lichen Planopilaris
- Trial Launch: Priovant commenced enrollment of the first subjects in a seamless Phase 2b/3 clinical trial for Lichen Planopilaris (LPP) in March 2026, marking the fourth indication in its late-stage development program and demonstrating the company's ongoing commitment to addressing high-morbidity autoimmune diseases.
- Urgent Market Need: LPP affects approximately 100,000 adults in the U.S., causing irreversible hair loss and permanent scarring, with no FDA-approved therapies available, highlighting Priovant's strategic importance in fulfilling this critical therapeutic gap.
- Drug Development Progress: Brepocitinib, a selective TYK2 and JAK1 inhibitor, has generated positive Phase 3 data in dermatomyositis, with its New Drug Application currently under FDA review, expected to receive approval in Q3 2026, further enhancing its potential in multi-indication development.
- Strategic Positioning: Priovant's CEO noted that expanding Brepocitinib into LPP aligns with its strategy in developing therapies for highly morbid orphan conditions, anticipating synergistic effects with the upcoming product launch in dermatomyositis to strengthen market competitiveness.
See More
Roivant Launches New Clinical Trial for LPP
- New Clinical Trial Launch: Roivant initiated a seamless Phase 2b/3 clinical trial for Lichen planopilaris (LPP) in March 2026, marking the fourth indication in its late-stage development program, demonstrating the company's proactive approach to addressing critical unmet therapeutic needs.
- FDA Priority Review: The FDA has granted Priority Review for the New Drug Application (NDA) of brepocitinib, with a target action date expected in Q3 2026, potentially accelerating market access for this treatment to meet urgent patient needs in LPP.
- Clinical Data Support: Strong mechanistic rationale and clinically meaningful results from an investigator-initiated placebo-controlled study support the rapid development of brepocitinib in LPP, highlighting its potential efficacy in this challenging condition.
- Multi-Indication Strategy: CEO Ben Zimmer emphasized that expanding brepocitinib into LPP aligns with the company's strategy of developing treatments for highly morbid orphan conditions, anticipating synergistic effects with other indications like dermatomyositis to enhance market competitiveness.
See More
S&P 500 Futures Rise in Pre-Market Session; United Therapeutics and Alcoa Take the Lead
Market Opening: U.S. stock markets are set to open in two hours.
United Therapeutics Corp. Performance: United Therapeutics Corp. (UTHR) saw a 12.9% increase in pre-market trading.
Alcoa Corp. Performance: Alcoa Corp. (AA) experienced a 9.3% rise in pre-market trading.
Overall Market Sentiment: The pre-market gains indicate positive sentiment among investors for these companies.
See More
Brepocitinib Shows Significant Benefits in Dermatomyositis Trial
- Clinical Trial Results: The Phase 3 VALOR trial demonstrated that brepocitinib 30 mg achieved a 15.3-point improvement in the Total Improvement Score (TIS) at Week 52 compared to placebo (P<0.001), indicating significant clinical benefits and potential in treating dermatomyositis.
- Adverse Event Management: Although the incidence of serious infections was higher in the brepocitinib 30 mg group compared to placebo, these events were resolved with medical management, and most patients completed treatment, suggesting a manageable safety profile.
- FDA Priority Review: The U.S. FDA has granted Priority Review for brepocitinib's New Drug Application (NDA) with a target action date set for Q3 2026, which could provide a new treatment option for patients with dermatomyositis if approved.
- Improvement in Quality of Life: Data presented at the AAD 2026 meeting indicated that 18.9% of patients in the brepocitinib 30 mg group achieved itch remission by Week 4, with sustained improvements in skin-related quality of life throughout the 52-week trial, highlighting its potential to enhance patient quality of life.
See More
ROIV Options Contract Analysis and Investment Opportunities
- Put Option Appeal: The current bid for the $27.00 put option is $1.50, meaning if an investor sells this contract, they commit to buying the stock at $27.00, effectively lowering their cost basis to $25.50, which is approximately a 7% discount from the current price of $28.98, making it attractive for those interested in ROIV.
- Yield Potential: Should the put option expire worthless, it would yield a 5.56% return on the cash commitment, or 7.07% annualized, referred to as YieldBoost, highlighting the potential attractiveness of this investment strategy.
- Call Option Returns: The $32.00 call option has a current bid of $2.00; if an investor buys ROIV shares at $28.98 and sells this call, they could achieve a total return of 17.32% if the stock is called away at expiration, indicating high return potential.
- Risk Assessment: Current analytical data suggests a 69% chance that the $27.00 put option will expire worthless, while the $32.00 call option has a 47% chance of expiring worthless, necessitating careful risk consideration for optimizing investment decisions.
See More
BlackBarn Capital Increases Warby Parker Stake by 2 Million Shares
- Stake Increase: BlackBarn Capital increased its stake in Warby Parker by 2 million shares during Q4 2025, with an estimated transaction value of $43.52 million, indicating confidence in the company despite a 15% decline in its stock price over the past year.
- Value Appreciation: The value of Warby Parker's position rose by $37.79 million at quarter-end, reflecting the impact of trading activity and stock price fluctuations, suggesting that BlackBarn Capital's investment strategy is proving effective.
- Asset Allocation Shift: Following the increase, Warby Parker now accounts for 4.3% of BlackBarn Capital's 13F reportable assets, indicating its significance in the investment portfolio, even though it does not rank among the top five holdings.
- Market Performance Insight: As of February 13, 2026, Warby Parker shares were priced at $22.46, underperforming the S&P 500 by 26.8 percentage points, prompting investors to monitor the company's ability to achieve sustainable growth in the optical retail market.
See More
Priovant Launches Phase 2b/3 Trial for Lichen Planopilaris
- Trial Launch: Priovant commenced enrollment of the first subjects in a seamless Phase 2b/3 clinical trial for Lichen Planopilaris (LPP) in March 2026, marking the fourth indication in its late-stage development program and demonstrating the company's ongoing commitment to addressing high-morbidity autoimmune diseases.
- Urgent Market Need: LPP affects approximately 100,000 adults in the U.S., causing irreversible hair loss and permanent scarring, with no FDA-approved therapies available, highlighting Priovant's strategic importance in fulfilling this critical therapeutic gap.
- Drug Development Progress: Brepocitinib, a selective TYK2 and JAK1 inhibitor, has generated positive Phase 3 data in dermatomyositis, with its New Drug Application currently under FDA review, expected to receive approval in Q3 2026, further enhancing its potential in multi-indication development.
- Strategic Positioning: Priovant's CEO noted that expanding Brepocitinib into LPP aligns with its strategy in developing therapies for highly morbid orphan conditions, anticipating synergistic effects with the upcoming product launch in dermatomyositis to strengthen market competitiveness.
See More
Roivant Launches New Clinical Trial for LPP
- New Clinical Trial Launch: Roivant initiated a seamless Phase 2b/3 clinical trial for Lichen planopilaris (LPP) in March 2026, marking the fourth indication in its late-stage development program, demonstrating the company's proactive approach to addressing critical unmet therapeutic needs.
- FDA Priority Review: The FDA has granted Priority Review for the New Drug Application (NDA) of brepocitinib, with a target action date expected in Q3 2026, potentially accelerating market access for this treatment to meet urgent patient needs in LPP.
- Clinical Data Support: Strong mechanistic rationale and clinically meaningful results from an investigator-initiated placebo-controlled study support the rapid development of brepocitinib in LPP, highlighting its potential efficacy in this challenging condition.
- Multi-Indication Strategy: CEO Ben Zimmer emphasized that expanding brepocitinib into LPP aligns with the company's strategy of developing treatments for highly morbid orphan conditions, anticipating synergistic effects with other indications like dermatomyositis to enhance market competitiveness.
See More
S&P 500 Futures Rise in Pre-Market Session; United Therapeutics and Alcoa Take the Lead
Market Opening: U.S. stock markets are set to open in two hours.
United Therapeutics Corp. Performance: United Therapeutics Corp. (UTHR) saw a 12.9% increase in pre-market trading.
Alcoa Corp. Performance: Alcoa Corp. (AA) experienced a 9.3% rise in pre-market trading.
Overall Market Sentiment: The pre-market gains indicate positive sentiment among investors for these companies.
See More
Brepocitinib Shows Significant Benefits in Dermatomyositis Trial
- Clinical Trial Results: The Phase 3 VALOR trial demonstrated that brepocitinib 30 mg achieved a 15.3-point improvement in the Total Improvement Score (TIS) at Week 52 compared to placebo (P<0.001), indicating significant clinical benefits and potential in treating dermatomyositis.
- Adverse Event Management: Although the incidence of serious infections was higher in the brepocitinib 30 mg group compared to placebo, these events were resolved with medical management, and most patients completed treatment, suggesting a manageable safety profile.
- FDA Priority Review: The U.S. FDA has granted Priority Review for brepocitinib's New Drug Application (NDA) with a target action date set for Q3 2026, which could provide a new treatment option for patients with dermatomyositis if approved.
- Improvement in Quality of Life: Data presented at the AAD 2026 meeting indicated that 18.9% of patients in the brepocitinib 30 mg group achieved itch remission by Week 4, with sustained improvements in skin-related quality of life throughout the 52-week trial, highlighting its potential to enhance patient quality of life.
See More
ROIV Options Contract Analysis and Investment Opportunities
- Put Option Appeal: The current bid for the $27.00 put option is $1.50, meaning if an investor sells this contract, they commit to buying the stock at $27.00, effectively lowering their cost basis to $25.50, which is approximately a 7% discount from the current price of $28.98, making it attractive for those interested in ROIV.
- Yield Potential: Should the put option expire worthless, it would yield a 5.56% return on the cash commitment, or 7.07% annualized, referred to as YieldBoost, highlighting the potential attractiveness of this investment strategy.
- Call Option Returns: The $32.00 call option has a current bid of $2.00; if an investor buys ROIV shares at $28.98 and sells this call, they could achieve a total return of 17.32% if the stock is called away at expiration, indicating high return potential.
- Risk Assessment: Current analytical data suggests a 69% chance that the $27.00 put option will expire worthless, while the $32.00 call option has a 47% chance of expiring worthless, necessitating careful risk consideration for optimizing investment decisions.
See More
BlackBarn Capital Increases Warby Parker Stake by 2 Million Shares
- Stake Increase: BlackBarn Capital increased its stake in Warby Parker by 2 million shares during Q4 2025, with an estimated transaction value of $43.52 million, indicating confidence in the company despite a 15% decline in its stock price over the past year.
- Value Appreciation: The value of Warby Parker's position rose by $37.79 million at quarter-end, reflecting the impact of trading activity and stock price fluctuations, suggesting that BlackBarn Capital's investment strategy is proving effective.
- Asset Allocation Shift: Following the increase, Warby Parker now accounts for 4.3% of BlackBarn Capital's 13F reportable assets, indicating its significance in the investment portfolio, even though it does not rank among the top five holdings.
- Market Performance Insight: As of February 13, 2026, Warby Parker shares were priced at $22.46, underperforming the S&P 500 by 26.8 percentage points, prompting investors to monitor the company's ability to achieve sustainable growth in the optical retail market.
See More
